This study investigated the efficacy and safety of TL-895, a second-generation BTK inhibitor, in patients with CLL/SLL. It showed promising results with high objective response rates and rapid clearance of leukemic compartments, especially in treatment-naïve patients. TL-895 also demonstrated a lower incidence of typical BTK inhibitor-related adverse events.

This phase II trial explored the combination of Ibrutinib and Venetoclax in CLL patients, revealing a 5-year progression-free survival of 90.1% and overall survival of 95.6%. The study highlighted the efficacy of this combination therapy, especially in patients with del(17p)/TP53 mutation.

This study analyzed clonal evolution and resistance mutations in CLL patients treated with Ibrutinib and Rituximab. It found that BTK/PLCG2 mutations were less common in upfront-treated patients, suggesting other factors contributing to disease progression.

This retrospective, multicenter Italian study evaluates the feasibility and tolerability of fixed-duration venetoclax-obinutuzumab (VO) in treatment-naïve chronic lymphocytic leukemia (CLL) in common clinical practice. It focuses on reasons for choosing fixed-duration VO over continuous BTK inhibitors. The study, conducted from May 2022 to June 2023, involved 790 patients, with 232 receiving fixed-duration VO. The main reasons for selecting VO were disease biology, treatment duration, comorbidities, and patient preference. The study found that most clinicians adhered to the VO schedule, with a low rate of patients discontinuing therapy due to toxicity.

This study analyzed the incidence of ventricular arrhythmias (VAs) and sudden deaths (SDs) in patients with chronic lymphocytic leukemia (CLL) treated with acalabrutinib, a next-generation Bruton tyrosine kinase inhibitor (BTKi). The analysis pooled data from five clinical trials, comparing acalabrutinib with standard-of-care therapies. The results showed that the risk of fatal VAs and SDs was low and similar between the acalabrutinib group and the comparator group. Nonfatal VAs were also comparable between the groups. The study concludes that acalabrutinib has a favorable safety profile regarding VAs and SDs, with risks comparable to standard-of-care treatments.

This pooled analysis of the CLL13 and CLL14 studies evaluates the toxicity and efficacy of venetoclax-obinutuzumab (Ven-Obi) in patients with treatment-naive chronic lymphocytic leukemia (CLL), categorized as fit or unfit. The study found that the overall response rate (ORR) and 3-year progression-free survival (PFS) rates were similar between unfit and fit patients, indicating that Ven-Obi is effective in both groups. Adverse events, including neutropenia, infusion-related reactions, and infections, were comparable between the groups, though infusion-related reactions and fatigue were more common in fit patients. Importantly, reduced venetoclax dose intensity did not significantly impact PFS, suggesting that dose modifications may not greatly affect long-term clinical outcomes.